Mylan announced Monday that it would be conducting a share repurchase for up to $1 billion, in a much faster timeline for repurchasing than most companies would give.
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
It is the best of both worlds for investors when large cap growth companies become inexpensive enough to have a value call.
With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably figures that if he can outlast the initial wave of negative publicity,…
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
The August 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Stocks toward the cheap consumption end of the economy tend to do better than capital goods stocks dependent on low interest rates.
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has secured financing…
ThinkstockTeva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43 in earnings per share (EPS) on $5.0 billion in revenue compared to…
Chris Lange Jon OggStocks were indicated higher on Tuesday morning after 5 days in a row of selling. Yet again we see the trend of investors finding a reason to buy every stock market…
